BASEL,
Switzerland, Oct 6
/PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEET:
MRES) (OTCQB: MRES)
POTENTIAL MARKET AND INCOME BASED ON 1 TEST; THE
SymPath®
The SymPath® test is part of the 12 tests that
Neuro-Biotech has the mandate to produce and distribute.
A brief list of statistics:
According to the World Health Organization
(WHO), 1 in every 4 people or 25% of individuals develops one or
more mental disorders at some stage in their life. Mental illnesses
are more common than cancer, diabetes or heart disease. These
illnesses do not discriminate; they can affect men, women, and
children, regardless of gender, race, ethnicity and socio-economic
status. Mental health issues represent 5 out of 10 leading causes
of disability worldwide; amounting to nearly one-third of the
disability in the world. Mental illness ranks first among illnesses
that cause disability in the United
States, Canada, and
Western Europe. It is predicted
that by the year 2010, depression will be the leading cause of
disability worldwide, not cancer, heart diseases, diabetes, or AIDS
(according to the World Health Organization (WHO)).
THE HUMAN COST
Unfortunately, almost 3,000 people commit
suicide every day in the world according to the WHO. For every
person that succeeds in taking their life there are at least 20
more who try. Suicide is a huge but largely preventable public
health problem, responsible for almost half of all violent deaths
and resulting in almost one million fatalities every year.
Estimates suggest the annual death rate could rise to 1.5 million
by the year 2020. In 90% of suicides, mental illness is the
attributing cause. Suicide is also one of the top three causes of
death among people between the ages of 15 and 34 years old. (Ref:
World Health Organization and ASHA International, an acronym
for A Source of Hope
for All touched by mental illness.)
ECONOMIC COST: Mental disorders cost billions of
dollars just in the United States
(US)!
Disorders have clear economic costs. While
numbers alone cannot convey the distress accompanying mental
disorders, the economic impact can be calculated. Sufferers and
their families or caregivers often experience reduced productivity
at home and in the workplace. These lost wages, combined with the
possibility of catastrophic health care expenditures, can seriously
affect the patient and their families' financial situation by
creating or worsening poverty. (Ref: WHO and ASHA
International)
Wherever the economic expenses of mental
disorders have been studied, the figures are staggering. The most
comprehensive set of estimates come from the US. Mental disorders
cost the United States more than
$150 billion each year for treatment,
for the outlay of social services and disability payments made for
patients, and for lost productivity and premature mortality. (Ref:
WHO and ASHA International)
TILL TODAY, this economic burden has not been
fully and effectively measured. This is because of the lack of
quantitative data and difficulties in measuring and evaluating.
SymPath® IS THE ANSWER: WHY?
Firstly, SymPath® assists the medical profession
in diagnosing patients, based on quantitative measurement, as
precise as current cholesterol tests. SymPath® allows determining
with accuracy the severity level of the patient's anxiety or
depressive state. By using our product, and based on an objective
quantified measure, the medical practitioner will now be able to
state, rather than subjectively determining the diagnosis, as is
currently the situation.
Furthermore SymPath® will eliminate the costly
and highly inefficient trial and errors currently performed by
physicians in prescribing their recommended remedy, which can waste
time and resources of the medical staff, and cause further harm for
patients. For instance, clients suffering from depression or stress
related disorders will immediately be identified through
Neuro-Biotech's SymPath® test.
No more guessing, medical professionals will not
only obtain accurate results, they will be able to properly
diagnose their patients and prescribe the appropriate therapeutic
approach and continued follow up with their patients.
PROJECTED MARKET PENETRATION AND REVENUE
In United
States alone, the health care sector includes more than
780,000 hospitals (Ref: First Research), clinics, doctor offices,
emergency care units, nursing homes and social services providers.
That figure includes 3059 Mental Health care institutions with 77
million people living in them. It would take 5,145 doctors? to meet
their needs. Those 77 million people will need at least 1 test to
evaluate their level, reducing by the fact the number of
practitioners. (Ref: Kaiser State Health Facts, Office of Shortage
Designation, Bureau of Health Professions, Health Resources and
Services Administration (HRSA), data as of 9/30/08)
Now let say that the 780,000 health care centers
order just one test per day each, it is relatively easy to make a
simple calculation when the average selling price per test is
around $50. Those figures are valid
for the United States and only for
the first test and we have 12 licenses!
The SymPath® has already been tested on several
thousand people in the world with an accuracy of 98.8%.
For more information, do not hesitate to contact
us by writing to info@neuro-agora.com and your request will be
transferred to the appropriate persons and we will get back to you
as soon as possible.
Contact:
Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
Forward Looking Statements
This release contains statements that are made pursuant to
the Safe Harbor Provisions of the Private Securities Litigation Act
of 1995. Certain statements in this press release may contain words
such as "anticipates," "believes," "could," "expects," "intends,"
"may," "projects," "targets" and other similar language that is
considered forward-looking statements. These forward-looking
statements are subject to certain risks and uncertainties and
persons reading this release are cautioned that such statements are
only predictions, and that the Company's actual future results or
performance may be materially different. The Company disclaims any
intention or obligation to update or revise forward-looking
information, whether as a result of new information, future events,
or otherwise, could cause the company's actual results to differ
materially from those indicated in any forward-looking
statements.
SOURCE Neuro-Biotech Corp.